跳转至内容
Merck
CN
所有图片(1)

主要文件

AB3430

Sigma-Aldrich

抗Prosurfactant蛋白B抗体,可与CT和NT反应

serum, Chemicon®

别名:

proSP-B

登录查看公司和协议定价


About This Item

UNSPSC代码:
12352203
eCl@ss:
32160702
NACRES:
NA.41

生物来源

rabbit

质量水平

抗体形式

serum

抗体产品类型

primary antibodies

克隆

polyclonal

种属反应性

human, mouse

制造商/商品名称

Chemicon®

技术

ELISA: suitable
immunohistochemistry: suitable
western blot: suitable

UniProt登记号

运输

wet ice

靶向翻译后修饰

unmodified

基因信息

human ... SFTPB(6439)

特异性

与人和小鼠proSP-B强烈反应(同时检测N末端和C末端前肽)。不与成熟SP-B反应。在人体组织上免疫染色肺泡II型细胞和非纤毛细支气管细胞。在小鼠组织上,免疫染色远端和终末气道中的肺泡II型细胞和非纤毛细支气管(Clara细胞)。

免疫原

人SP-B(前)前蛋白的全长重组肽(381 a.a.)。
表位:同时与C末端和N末端反应

应用

使用该抗前表面活性物质蛋白B抗体检测前表面活性物质蛋白B,该抗体与经验证可用于ELISA、IH &WB的C末端&N末端均反应。
免疫组化:在有和没有抗原修复的人体组织上为1:4,000-1:8,000(请参见背面的方案),在成年和胎儿小鼠肺上为1:1,000-1:2,000(请参见背面的注释)。

免疫印迹:1:1,000-1:5,000;前蛋白42-46kDa。

ELISA:1:500-1:1,000

最佳稀释度必须由最终用户确定。
研究子类别
离子&运输通道
研究类别
代谢

外形

兔血清。调理液。不含防腐剂。

储存及稳定性

以未稀释的等分试样保存于-20°C下12个月。应避免反复冻/融循环。

法律信息

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

免责声明

除非我们的产品目录或产品附带的其他公司文档另有说明,否则我们的产品仅供研究使用,不得用于任何其他目的,包括但不限于未经授权的商业用途、体外诊断用途、离体或体内治疗用途或任何类型的消费或应用于人类或动物。

未找到合适的产品?  

试试我们的产品选型工具.

储存分类代码

10 - Combustible liquids

WGK

WGK 1

闪点(°F)

Not applicable

闪点(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Raffaele Gerlini et al.
Cell death & disease, 10(10), 747-747 (2019-10-05)
The serine-threonine kinase homeodomain-interacting protein kinase 2 (HIPK2) modulates important cellular functions during development, acting as a signal integrator of a wide variety of stress signals, and as a regulator of transcription factors and cofactors. We have previously demonstrated that
Shashi P Singh et al.
Environmental health perspectives, 121(8), 957-964 (2013-06-13)
Cigarette smoke (CS) exposure during gestation may increase the risk of bronchopulmonary dysplasia (BPD)-a developmental lung condition primarily seen in neonates that is characterized by hypoalveolarization, decreased angiogenesis, and diminished surfactant protein production and may increase the risk of chronic
Jonathan M Charest et al.
Biomaterials, 52, 79-87 (2015-03-31)
The primary treatment for end-stage lung disease is lung transplantation. However, donor organ shortage remains a major barrier for many patients. In recent years, techniques for maintaining lungs ex vivo for evaluation and short-term (<12 h) resuscitation have come into
Daniel J Wegner et al.
Acta paediatrica (Oslo, Norway : 1992), 96(4), 516-520 (2007-03-30)
Loss of function mutations in the surfactant protein-B gene (SFTPB) cause lethal neonatal respiratory distress due to reduced or absent expression of mature surfactant protein B (SP-B, encoded in exons 6 and 7). No large deletions in SFTPB have been
Jeanne-Marie Krischer et al.
Histochemistry and cell biology, 155(2), 183-202 (2020-11-15)
Mechanical ventilation triggers the manifestation of lung injury and pre-injured lungs are more susceptible. Ventilation-induced abnormalities of alveolar surfactant are involved in injury progression. The effects of mechanical ventilation on the surfactant system might be different in healthy compared to

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门